Nyxoah (NASDAQ:NYXH) used its presentation at Oppenheimer’s MedTech and Services Conference 2026 to outline the company’s ...

The FDA approved a proximal hypoglossal nerve stimulation device (aura6000 system) for adults with moderate to severe ...

Fact checked by Jennifer Klump Meet the Author Smita Patel, DO is an integrative neurologist and is affiliated with Endeavor Health. She is triple board-certified in neurology, sleep medicine, and ...

With a steady rise in patients suffering from sleep-related breathing disorders, PGIMER is planning to set up an additional sleep laboratory to manage the growing load and improve early diagnosis.

Hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning ...

Philips has announced that DreamStation BiPAP AVAPS devices have been designated as medical necessary for lower-weight patients with breathing impairment.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the ...

LivaNova (Nasdaq:LIVN) announced today that it received FDA premarket approval (PMA) for its aura6000 neuromodulation system for sleep apnea.

GLP-1 medications, such as Ozempic, Zepbound and Wegovy, have emerged as a significant advancement in the treatment of various conditions, including Type 2 diabetes, heart ...

A 2026 source-based informational overview of SnoreStop's doctor-developed oral spray formula as described in company materials, cited clinical study references, homeopathic ingredient research ...

Do you sleep like a soldier at night? On your back, stiff, seemingly ready to jump up at a moment’s notice? Back sleepers, ...